Search results for "Therapy"

showing 10 items of 12482 documents

Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor).

2017

Perivascular epithelioid cell tumors (PEComas) are infrequent neoplasms with peculiar myomelanocytic differentiation. The aggressive abdominopelvic variant is rare, with only a small number of published cases. We present an additional case of this unusual variant, which showed an aggressive histologic and clinical behavior with multiple liver metastases and resistance to several therapies. We also discuss the histological and immunohistochemical profiles as well as the differential diagnosis.

0301 basic medicineAdultPathologymedicine.medical_specialtyPerivascular Epithelioid Cell Neoplasmsmedicine.medical_treatmentAntineoplastic AgentsDiseasePathology and Forensic MedicineTargeted therapy03 medical and health sciences0302 clinical medicineMedicineHumansMolecular Targeted TherapyChemotherapybusiness.industryTOR Serine-Threonine Kinasesmedicine.diseasePerivascular Epithelioid Cell Tumors030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisImmunohistochemistrySurgeryFemaleSarcomaAnatomyDifferential diagnosisbusinessInternational journal of surgical pathology
researchProduct

Diabetic thoracic radiculopathy: a case of a young woman with clinical improvement following immunotherapy.

2020

Thoracic radiculopathy is a rare cause of thoracic-abdominal or abdominal pain in subjects with poorly controlled diabetes. We present a case of a young woman with type I diabetes and a severe abdominal pain in both lower quadrants. An extensive diagnostic gastroenterological and gynaecological workup did not disclose abnormalities. Electromyography revealed an initial polyneuropathy and significant neurogenic abnormalities in the T10-T12 paravertebral muscles. Following the hypothesis that the radiculopathy-related abdominal pain might have an immuno-mediated pathogenesis, the patient underwent a complex trial of immunotherapy, which was accompanied by a sustained improvement over months t…

0301 basic medicineAdultmedicine.medical_specialtyAbdominal painmedicine.medical_treatmentElectromyography030105 genetics & heredityThoracic VertebraePathogenesis03 medical and health sciences0302 clinical medicineFull recoveryRare DiseaseDiabetes mellitusmedicineHumansRadiculopathymedicine.diagnostic_testbusiness.industryElectromyographyMusclesImmunoglobulins IntravenousGeneral MedicineImmunotherapymedicine.diseaseSurgeryAbdominal PainDiabetes Mellitus Type 1Treatment OutcomeFemaleImmunotherapymedicine.symptombusinessPolyneuropathy030217 neurology & neurosurgeryDiabetic thoracic radiculopathyBMJ case reports
researchProduct

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric …

2021

Claudin 18.2 (CLDN18.2) is contained within normal gastric mucosa epithelial tight junctions; upon malignant transformation, CLDN18.2 epitopes become exposed. Zolbetuximab, a chimeric monoclonal antibody, mediates specific killing of CLDN18.2-positive cells through immune effector mechanisms.The FAST study enrolled advanced gastric/gastro-oesophageal junction and oesophageal adenocarcinoma patients (aged ≥18 years) with moderate-to-strong CLDN18.2 expression in ≥40% tumour cells. Patients received first-line epirubicin + oxaliplatin + capecitabine (EOX, arm 1, n = 84) every 3 weeks (Q3W), or zolbetuximab + EOX (loading dose, 800 mg/mIn the overall population, both PFS [hazard ratio (HR) = 0…

0301 basic medicineAdultmedicine.medical_specialtyAdolescentEsophageal NeoplasmsPopulationMedizinPhases of clinical researchAdenocarcinomaGastroenterologyLoading doseCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationCapecitabineeducation.field_of_studybusiness.industryHazard ratioAntibodies MonoclonalHematologyOxaliplatin030104 developmental biologyOncology030220 oncology & carcinogenesisClaudinsEsophagogastric Junctionbusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

2018

Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment–refractory (RR)-AML. Using an international multicenter retrospective database, we studied the effectiveness of HMAs in RR-AML and evaluated for predictors of response and overall survival (OS). A total of 655 patients from 12 centers received azacitidine (57%) or decitabine (43%), including 290 refractory (44%) and 365 relapsed (56%) patients. Median age at diagnosis was 65 years. Best response to HMAs was complete remission (CR; 11%) or CR with incomplete count recovery (CRi; 5.3%). …

0301 basic medicineAdultmedicine.medical_specialtyAntimetabolites AntineoplasticMyeloidAdolescentDatabases FactualAzacitidineDecitabineSalvage therapyDecitabineCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineRefractoryInternal medicinehemic and lymphatic diseasesmedicineHumansSurvival analysisAgedRetrospective StudiesAged 80 and overSalvage TherapyMyeloid Neoplasiabusiness.industryRemission InductionRetrospective cohort studyHematologyDNA MethylationMiddle Agedmedicine.diseasePrognosisSurvival AnalysisLeukemiaLeukemia Myeloid Acute030104 developmental biologymedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisAdolescent; Adult; Aged; Aged 80 and over; Antimetabolites Antineoplastic; Cohort Studies; DNA Methylation; Databases Factual; Decitabine; Humans; Leukemia Myeloid Acute; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Young Adultbusinessmedicine.drug
researchProduct

Head, Neck, and Abdominopelvic Septic Thrombophlebitis: Current Evidence and Challenges in Diagnosis and Treatment.

2020

AbstractSeptic thrombophlebitis (STP) is a complex, cross-disciplinary clinical condition that combines a localized infection with a neighboring venous thrombosis. STP can occur at several possible anatomic sites, such as dural sinuses, jugular vein (Lemierre syndrome), portal vein (pylephlebitis), and pelvic veins. Its high mortality in the preantibiotic era improved considerably with the introduction of modern antibiotics. However, little evidence exists to date to guide its clinical management. The incidence of STP or its risk factors may be increasing, and its mortality may still be considerable. These trends would have far-reaching implications, especially in the setting of increasing …

0301 basic medicineAdultmedicine.medical_specialtyPylephlebitismedicine.drug_class030204 cardiovascular system & hematologyThrombophlebitisPelvis03 medical and health sciences0302 clinical medicineRisk FactorsJugular veinSepsisAbdomenMedicineHumansSeptic thrombophlebitisIntensive care medicineVenous Thrombosisbusiness.industryPortal VeinIncidence (epidemiology)IncidenceAnticoagulantAnticoagulantsHematologyBacterial InfectionsLemierre SyndromeThrombophlebitismedicine.diseaseAnti-Bacterial AgentsVenous thrombosis030104 developmental biologyObservational studyDrug Therapy CombinationFemaleJugular VeinsbusinessHeadNeckHamostaseologie
researchProduct

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer…

2016

Summary Background In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological complete response compared with those given trastuzumab and docetaxel after surgery. Here, we report 5-year progression-free survival, disease-free survival, and safety. Methods In this multicentre, open-label, phase 2 randomised trial in hospitals and medical clinics, treatment-naive adults with locally advanced, inflammatory, or early-stage HER2-positive breast cancer were randomly assigned (1:1:1:1) to receive four neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus do…

0301 basic medicineAdultmedicine.medical_specialtyTime FactorsAdolescentReceptor ErbB-2PopulationAntibodies Monoclonal HumanizedGastroenterologyGroup B03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overeducation.field_of_studybusiness.industryMiddle AgedTrastuzumabmedicine.diseasePrognosisNeoadjuvant TherapySurgerySurvival Rate030104 developmental biologyOncologyDocetaxelTolerabilityChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleInflammatory Breast NeoplasmsPertuzumabNeoplasm Recurrence LocalbusinessFebrile neutropeniamedicine.drugEpirubicinFollow-Up StudiesThe Lancet. Oncology
researchProduct

Safety of Novel Amino-5-laevulinate Photosensitizer Precursors in Photodynamic Therapy for Healthy Human Skin.

2015

Peer reviewed

0301 basic medicineAdultmedicine.medical_specialtyTime Factorsmedicine.medical_treatmenteducationPain5-AMINOLEVULINIC ACIDHuman skinPhotodynamic therapyPilot ProjectsEUROPEAN GUIDELINESDermatology030105 genetics & heredityAdministration Cutaneousphotodynamic therapy (PDT)ihosyöpä03 medical and health sciencesDouble-Blind MethodMedicineHumansPhotosensitizerProdrugsSkinACTINIC KERATOSESihoPhotosensitizing Agentsbusiness.industryGeneral MedicineActinic keratosesAminolevulinic AcidDermatologyHealthy Volunteers3. Good healthOikeuslääketiede ja muut lääketieteet - Forensic science and other medical sciencesREDUCES INFLAMMATIONPhotochemotherapyErythema3121 General medicine internal medicine and other clinical medicinebusinessActa dermato-venereologica
researchProduct

Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms

2017

Life expectancy and the number of elderly people are progressively increasing around the world. Together with other pathologies, allergic diseases also show an increasing incidence in geriatric age. This is partly due to the growing emphasis on a more accurate and careful diagnosis of the molecular mechanisms that do not allow to ignore the real pathogenesis of many symptoms until now unknown, and partly to the fact that the allergic people from 20 years ago represent the elderly population now. Moreover, environmental pollution predisposes to the onset of allergic asthma and dermatitis which are the result of internal pathologies more than the expression of allergic manifestations. At the …

0301 basic medicineAgingAllergyAllergyUrticariamedicine.medical_treatmentImmunologyEnvironmental pollutionReviewSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesElderlyImmune systemAnaphylaxiFood allergyFood allergymedicineImmunology and AllergyAnaphylaxisMolecular BiologyAsthmabusiness.industryConjunctivitiImmunotherapyConjunctivitismedicine.diseaseAsthmaDrug reaction030104 developmental biologyageAging; Allergy; Anaphylaxis; Asthma; Conjunctivitis; Drug reaction; Elderly; Food allergy; Immunotherapy; Urticaria; Immunology and Allergy; Immunology; Molecular BiologyImmunologyLife expectancyImmunotherapybusinessAnaphylaxisClinical and Molecular Allergy
researchProduct

Targeting Nitric Oxide with Natural Derived Compounds as a Therapeutic Strategy in Vascular Diseases

2016

Within the family of endogenous gasotransmitters, nitric oxide (NO) is the smallest gaseous intercellular messenger involved in the modulation of several processes, such as blood flow and platelet aggregation control, essential to maintain vascular homeostasis. NO is produced by nitric oxide synthases (NOS) and its effects are mediated by cGMP-dependent or cGMP-independent mechanisms. Growing evidence suggests a crosstalk between the NO signaling and the occurrence of oxidative stress in the onset and progression of vascular diseases, such as hypertension, heart failure, ischemia, and stroke. For these reasons, NO is considered as an emerging molecular target for developing therapeutic stra…

0301 basic medicineAgingPhytochemicalsIschemiaEndogenyReview Article030204 cardiovascular system & hematologyPharmacologyBiologyNitric Oxidemedicine.disease_causeCardiovascular SystemBiochemistryNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineAnimalsHumansVascular Diseasescell biology; aging; biochemistrylcsh:QH573-671GasotransmittersPlants Medicinallcsh:CytologyPolyphenolsCardiovascular AgentsCell BiologyGeneral Medicinemedicine.diseaseDietOxidative StressCrosstalk (biology)030104 developmental biologychemistryHeart failurePlant PreparationsOxidative stressIntracellularPhytotherapySignal TransductionOxidative Medicine and Cellular Longevity
researchProduct

Decreased bioavailability of nitric oxide in aorta from ovariectomized senescent mice. Role of cyclooxygenase.

2015

This study investigates the effects of aging and/or ovariectomy on vascular reactivity to thromboxane A2 (TXA2) receptor stimulation with U46619, and the modulation by nitric oxide (NO) and cyclooxygenase (COX) in aorta from female senescence-accelerated mice (SAMP8) and from senescence resistant mice (SAMR1). Five-month-old female SAMR1 and SAMP8 were divided into three groups: sham-operated, ovariectomized and ovariectomized plus estradiol. Twenty-eight days after surgery, thoracic aortic rings were mounted for isometric recording of tension and concentration-response curves for U46619 (10(-10)-3 × 10(-7) M) were performed in the absence and in the presence of the NO synthase inhibitor N(…

0301 basic medicineAgingReceptors ThromboxaneAorta Thoracic030204 cardiovascular system & hematologyBiochemistrychemistry.chemical_compoundThromboxane A2Mice0302 clinical medicineEndocrinologySuperoxidesThoracic aortaVasoconstrictor AgentsbiologyEstradiolSuperoxideEstrogen Replacement TherapyAge FactorsOvariectomized ratFemaleMenopauseSignal Transductionmedicine.medical_specialtymedicine.drug_classOvariectomyDown-RegulationNitric OxideNitric oxide03 medical and health sciencesThromboxane A2medicine.arteryInternal medicineGeneticsmedicineAnimalsCyclooxygenase InhibitorsMolecular BiologyAortaDose-Response Relationship Drugbusiness.industryCell BiologyEnzyme ActivationOxidative Stress030104 developmental biologyEndocrinologychemistryEstrogenProstaglandin-Endoperoxide SynthasesVasoconstrictionbiology.proteinCyclooxygenaseNitric Oxide SynthasebusinessExperimental gerontology
researchProduct